Prosecution Insights
Prosecution Insights
8 pending office actions • 5 clients • 8 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| §102 only | 1 (12%) |
| §112 only | 2 (25%) |
| No statute on record | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LOCKARD, JON MCCLELLAND | 1 | 74.5% | +27.0% |
| ELENISTE, PIERRE PAUL | 1 | 38.5% | +30.2% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 56.8% | +41.6% |
| DUFFY, BRADLEY | 1 | 54.4% | +45.4% |
| WEDDINGTON, KEVIN E | 1 | 75.3% | +9.9% |
| LEVERETT, MARY CHANG | 1 | 60.5% | +22.6% |
| MAHLUM, JONATHAN DAVIS | 1 | 57.7% | +6.9% |
| BRISTOL, LYNN ANNE | 1 | 63.7% | +39.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550571 | PLASMA KALLIKREIN INHIBITORS | ROBINSON, MIKHAIL O'DONNEL | 79d overdue |
| 18263753 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR ROR1 AND CD3 | DUFFY, BRADLEY | 31d overdue |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | LEVERETT, MARY CHANG | 30d |
| 18695502 | METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS | LOCKARD, JON MCCLELLAND | 40d |
| 18550486 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | ELENISTE, PIERRE PAUL | 69d |
| 17822959 | NOVEL ANTIBODY FRAMEWORKS | BRISTOL, LYNN ANNE | 78d |
| Client (Assignee) | Pending OAs |
|---|---|
| Aslan Pharmaceuticals | 2 |
| Takeda | 2 |
| Numab Therapeutics AG | 2 |
| UMC UTRECHT HOLDING B.V. | 1 |
| Julius-Maximilians-Universität Würzburg | 1 |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1647 | 1 |
| 1622 | 1 |
| 1627 | 1 |
| 1629 | 1 |
| 1687 | 1 |
| 1625 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18695502 | METHOD FOR TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS | Aslan Pharmaceuticals Pte Ltd | LOCKARD, JON MCCLELLAND | 1647 | Other | Final Rejection | 40d | Pending | Mar 26, 2024 |
| 18550486 | POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited | ELENISTE, PIERRE PAUL | 1622 | §102 | Non-Final OA | 69d | Pending | Sep 14, 2023 |
| 18550571 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited | ROBINSON, MIKHAIL O'DONNEL | 1627 | Other | Non-Final OA | 79d overdue | Pending | Sep 14, 2023 |
| 18263753 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR ROR1 AND CD3 | Numab Therapeutics AG | DUFFY, BRADLEY | 1643 | §112 | Non-Final OA | 31d overdue | Pending | Aug 01, 2023 |
| 18184657 | TREATMENT OF AUTOIMMUNE SKIN DISEASE | Aslan Pharmaceuticals Pte Ltd | WEDDINGTON, KEVIN E | 1629 | §103 | Non-Final OA | 182d overdue | Pending | Mar 16, 2023 |
| 17995525 | METHOD FOR IDENTIFYING SIGNATURES FOR PREDICTING TREATMENT RESPONSE | UMC Utrecht Holding B.V. | LEVERETT, MARY CHANG | 1687 | §103 | Non-Final OA | 30d | Pending | Oct 05, 2022 |
| 17906184 | PROTEOLYSIS TARGETING CHIMERA (PROTAC) FOR DEGRADATION OF AURORA A-KINASE | Julius-Maximilians-Universitaet Wuerzburg | MAHLUM, JONATHAN DAVIS | 1625 | §103 | Non-Final OA | 80d overdue | Pending | Sep 12, 2022 |
| 17822959 | NOVEL ANTIBODY FRAMEWORKS | Numab Therapeutics AG | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 78d | Pending | Aug 29, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial